By Sian Lazell
Animal Pharm News
June 9, 2016
Nexvet Biopharma has presented additional data from clinical studies of its canine and feline anti-nerve growth factor (anti-NGF) monoclonal antibody (mAB) pain therapy candidates.
Ranevetmab (NV-01) and Frunevetmab (NV-02) are being developed as monthly subcutaneous injectables for the control of pain associated with canine osteoarthritis and feline osteoarthritis, respectively.
The additional data showed no significant adverse safety events were detected in clinical studies of both candidates. In addition, both demonstrated a wide variety of statistically significant improvements over a placebo at multiple time points, using multiple assessment methods.
Nexvet previously reported key pivotal data for Ranvetmab in November 2015 and plans to initiate a pivotal efficacy and field safety study for Frunevetmab this year, following a positive pilot field study.
The Ireland-headquartered firm explained chronic pain associated with osteoarthritis creates significant morbidity in companion animal populations.
At present, non-steroidal anti-inflammatory drugs are commonly used to treat dogs but the company said this treatment is limited. It added there are currently no approved therapies for long-term use in cats in the US.
Chief executive of the firm Dr Mark Heffernan said: "The Nexvet team are delighted to share these data with the veterinary community, and are excited about the opportunities these products could bring to the veterinary community and industry."
Recently, Nexvet began production at its new BioNua veterinary biologics manufacturing facility in Tullamore, Ireland.